InSphero CEO Jan Lichtenberg extends holiday greetings from our teams in Switzerland and the United States, and looks back on the highlights of 2020: a tumultuous year shaped by a […]
An ongoing challenge in NASH Drug Discovery is selecting “fit for purpose” models for preclinical drug screening. InSphero liver expert Sue Grepper and Head of Liver Solutions Eva Thoma recently […]
As the coronavirus epidemic prompts cancellations of scientific meetings around the world, we have been working on alternative methods to keep you informed of advances in 3D cell-based assay technology, […]
InSphero CEO Jan Lichtenberg muses about how far 3D cell technology has come since InSphero was founded in 2009 and shares the latest news about how our disruptive 3D technology […]
Model systems, whether laboratory animals or human cell-based systems, have long been central to the discovery and development of new and better drugs for the treatment of human disease. But […]
InSphero Senior Application Scientist Sue Grepper explains why critical limitations of dietary and genetically modified rodent models for NASH may be slowing down drug discovery efforts in this blog. She […]
InSphero CEO Jan Lichtenberg and renowned liver disease expert Dr. Scott Friedman of the Icahn School of Medicine at Mount Sinai recently talked to PharmaExec magazine about how to resolve […]
Pharma companies racing to develop new drugs to combat chronic liver diseases, such as NASH and fibrosis, need better preclinical testing tools for compound screening and mechanistic studies. Here's how […]
In honor of the inaugural International NASH Day, an initiative to raise awareness of nonalcoholic steatohepatitis (NASH), I thought it would be appropriate to reflect on the current status of […]